-
E125706-10mgEI1 is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.
-
E125706-25mgEI1 is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.
-
E125706-50mgEI1 is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.
-
E125706-5mgEI1 is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.
-
-
-
E413061-100mgInformationElafibranor (GFT505) is an agonist of theperoxisome proliferator-activated receptor-α(PPAR-alpha)andperoxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and
-
E413061-10mgInformationElafibranor (GFT505) is an agonist of theperoxisome proliferator-activated receptor-α(PPAR-alpha)andperoxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and
-
E413061-25mgInformationElafibranor (GFT505) is an agonist of theperoxisome proliferator-activated receptor-α(PPAR-alpha)andperoxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and
-
E413061-50mgInformationElafibranor (GFT505) is an agonist of theperoxisome proliferator-activated receptor-α(PPAR-alpha)andperoxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and
-
E413061-5mgInformationElafibranor (GFT505) is an agonist of theperoxisome proliferator-activated receptor-α(PPAR-alpha)andperoxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and
-